CL2021000343A1 - Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128) - Google Patents

Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)

Info

Publication number
CL2021000343A1
CL2021000343A1 CL2021000343A CL2021000343A CL2021000343A1 CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1 CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A CL2021000343 A CL 2021000343A CL 2021000343 A1 CL2021000343 A1 CL 2021000343A1
Authority
CL
Chile
Prior art keywords
interleukin
peptide inhibitors
divisional application
receptor peptide
receptor
Prior art date
Application number
CL2021000343A
Other languages
Spanish (es)
Inventor
Gregory Bourne
Xiaoli Cheng
Brian Troy Frederick
Jie Zhang
Dinesh V Patel
David Liu
Ashok Bhandari
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of CL2021000343A1 publication Critical patent/CL2021000343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 que se pueden utilizar para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatorias.The present invention provides novel peptide inhibitors of the interleukin 23 receptor that can be used for the treatment or prevention of various diseases and disorders, including inflammatory bowel diseases.

CL2021000343A 2015-07-15 2021-02-09 Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128) CL2021000343A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20

Publications (1)

Publication Number Publication Date
CL2021000343A1 true CL2021000343A1 (en) 2021-08-06

Family

ID=57757647

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018000128A CL2018000128A1 (en) 2015-07-15 2018-01-15 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases
CL2018003322A CL2018003322A1 (en) 2015-07-15 2018-11-22 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)
CL2021000343A CL2021000343A1 (en) 2015-07-15 2021-02-09 Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2018000128A CL2018000128A1 (en) 2015-07-15 2018-01-15 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases
CL2018003322A CL2018003322A1 (en) 2015-07-15 2018-11-22 Interleukin 23 receptor peptide inhibitors and their use to treat inflammatory diseases. (divisional application 201800128)

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (2) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX2018000542A (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704744T3 (en) 2012-06-13 2019-03-19 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
WO2014145561A2 (en) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
CN109776525B (en) 2013-04-19 2022-01-21 因赛特控股公司 Bicyclic heterocycles as FGFR inhibitors
ES2890600T3 (en) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Alpha4beta7 integrin antagonist thioether peptides
KR102482790B1 (en) 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (en) 2016-03-23 2019-01-11 领导医疗有限公司 Method for synthesizing 4 β of α, 7 peptide antagonists
EP3570864A4 (en) * 2017-01-18 2020-12-30 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
MX2020011639A (en) 2018-05-04 2021-02-15 Incyte Corp Salts of an fgfr inhibitor.
BR112020022392A2 (en) 2018-05-04 2021-02-02 Incyte Corporation solid forms of a fgfr inhibitor and processes for preparing them
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114341161A (en) * 2019-07-10 2022-04-12 领导医疗有限公司 Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JOP20220169A1 (en) * 2020-01-15 2023-01-30 Janssen Biotech Inc Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20230110570A (en) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. Compositions of Peptide Inhibitors of the Interleukin-23 Receptor
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20240034223A (en) * 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 Bicyclic peptide inhibitors of the interleukin-23 receptor
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists
US20240218014A1 (en) * 2022-11-21 2024-07-04 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
WO2024155547A2 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
WO2024163643A1 (en) 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2692037A1 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) * 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
KR102482790B1 (en) * 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Also Published As

Publication number Publication date
AU2016293619A1 (en) 2018-02-01
DOP2018000010A (en) 2018-03-30
CO2018000349A2 (en) 2018-07-10
NI201800008A (en) 2018-06-29
ECSP18002929A (en) 2018-03-31
SV2018005614A (en) 2018-05-22
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
CL2018003322A1 (en) 2019-01-18
BR112018000691A2 (en) 2018-09-18
EA201890325A1 (en) 2018-06-29
SG10201912066SA (en) 2020-02-27
JP2018522008A (en) 2018-08-09
CR20180029A (en) 2018-06-05
JP6858174B2 (en) 2021-04-14
HK1259149A1 (en) 2019-11-29
CN108348580A (en) 2018-07-31
EA035733B9 (en) 2021-01-14
CN108348580B (en) 2022-05-10
HK1257747A1 (en) 2019-10-25
UA123772C2 (en) 2021-06-02
KR20180030663A (en) 2018-03-23
WO2017011820A3 (en) 2017-02-23
CL2018000128A1 (en) 2018-06-15
EP3341011A2 (en) 2018-07-04
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (en) 2023-03-27
MX2018000542A (en) 2018-06-27
EA035733B1 (en) 2020-07-31
PE20180571A1 (en) 2018-04-04
CA2991984A1 (en) 2017-01-19
IL256827A (en) 2018-03-29
WO2017011820A2 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
CL2021000343A1 (en) Interleukin 23 Receptor Peptide Inhibitors (Divisional Application No. 201800128)
CY1124013T1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
CL2018001349A1 (en) Compositions comprising bacterial strains
CL2018001367A1 (en) Compositions comprising bacterial strains
CO2017013446A2 (en) Compositions comprising bacterial strains of the genus Bacteroides
CL2018001368A1 (en) Compositions comprising bacterial strains
CO2017013443A2 (en) Compositions comprising bacterial strains of the genus Blautia
CL2017003142A1 (en) Compositions comprising bacterial strains
CL2018001358A1 (en) Compositions comprising bacterial strains
ECSP19015192A (en) COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
BR112019012062A2 (en) treating a gastrointestinal tract disease with a jak inhibitor and devices
EA201691134A1 (en) NEW GLUTAMINASE INHIBITORS
CR20190394A (en) AUTOTAXIN INHIBITOR COMPOUNDS(Divisional de Exp. 2016-0289)
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
PL410665A1 (en) Arginase inhibitors and their therapeutical applications
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
CL2016002321A1 (en) Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders.
MA40642A (en) Novel peptide derivatives and uses thereof
AR106769A1 (en) COMPOSITIONS THAT INCLUDE BACTERIAL VINTAGES